Case Study 1: AstraZeneca Fighting a Global Pandemic AstraZeneca is a global bio-pharmaceutical company headquartered in Cambridge, England, with revenues of $26.6 billion (2020). CHALLENGE: From Lab to Jab at Light Speed As COVID-19 spread throughout the world in the spring of 2020, AstraZeneca recognized the need for an effective COVID-19 vaccine to defeat the virus. In April 2020 AstraZeneca joined forces with the University of Oxford to make a meaningful difference and save lives. This landmark partnership brought together world-class expertise in vaccinology with AstraZeneca’s ability to deliver a global solution at scale. AstraZeneca’s research partners at Oxford University had demonstrated an immune response in preclinical studies and some encouraging early clinical results that provided a basis for confidence that a vaccine could be rapidly developed. AstraZeneca’s proven manufacturing capability and global supply chain would enable rapid progress from the research lab to developing a highly effective vaccine with a favorable safety profile that could be administered worldwide. AstraZeneca and Oxford University pledged to provide the vaccine on a not-for-profit basis. This commitment to broad and equitable access ensured that the vaccine would be available at cost during the pandemic and accessible to low-income countries after the pandemic subsided. To be successful, however, AstraZeneca would have to make every dollar count. Question Who are the 2 primary stakeholders?

Principles Of Marketing

17th Edition

ISBN:9780134492513

Author:Kotler, Philip, Armstrong, Gary (gary M.)

Publisher:Kotler, Philip, Armstrong, Gary (gary M.)

Chapter1: Marketing: Creating Customer Value And Engagement

Section: Chapter Questions

Problem 1.1DQ

See similar textbooks

Related questions

Question

Case Study 1: AstraZeneca Fighting a Global Pandemic

AstraZeneca is a global bio-pharmaceutical company headquartered in Cambridge, England, with revenues of $26.6 billion (2020).

CHALLENGE: From Lab to Jab at Light Speed

As COVID-19 spread throughout the world in the spring of 2020, AstraZeneca recognized the need for an effective COVID-19 vaccine to defeat the virus. In April 2020 AstraZeneca joined forces with the University of Oxford to make a meaningful difference and save lives. This landmark partnership brought together world-class expertise in vaccinology with AstraZeneca’s ability to deliver a global solution at scale. AstraZeneca’s research partners at Oxford University had demonstrated an immune response in preclinical studies and some encouraging early clinical results that provided a basis for confidence that a vaccine could be rapidly developed.

AstraZeneca’s proven manufacturing capability and global supply chain would enable rapid progress from the research lab to developing a highly effective vaccine with a favorable safety profile that could be administered worldwide. AstraZeneca and Oxford University pledged to provide the vaccine on a not-for-profit basis. This commitment to broad and equitable access ensured that the vaccine would be available at cost during the pandemic and accessible to low-income countries after the pandemic subsided. To be successful, however, AstraZeneca would have to make every dollar count.

Question

Who are the 2 primary stakeholders?

Definition Definition Arrangement between two or more people whereby they agree to manage business operations and share its profits and losses in an agreed ratio. The agreement drafted and signed by the partners of the firm is termed as a partnership deed and contains various important clauses agreed between the partners such as profit/loss sharing, interest on capital, remuneration allocation of each partner, and drawings of a partner.

Expert Solution